Cargando…
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of adenocarcinoma tumour histology. Nintedanib competitively binds to the kinase domains of vascular endothelial growth factor...
Autores principales: | Wind, Sven, Schmid, Ulrike, Freiwald, Matthias, Marzin, Kristell, Lotz, Ralf, Ebner, Thomas, Stopfer, Peter, Dallinger, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719436/ https://www.ncbi.nlm.nih.gov/pubmed/31016670 http://dx.doi.org/10.1007/s40262-019-00766-0 |
Ejemplares similares
-
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
por: Wind, Sven, et al.
Publicado: (2016) -
Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017) -
Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects
por: Luedtke, Doreen, et al.
Publicado: (2018) -
Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis
por: Schmid, Ulrike, et al.
Publicado: (2017) -
A Drug–Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
por: Vonk, Madelon C., et al.
Publicado: (2021)